nodes	percent_of_prediction	percent_of_DWPC	metapath
Captopril—MMP2—bone cancer	0.439	0.603	CbGaD
Captopril—MMP9—bone cancer	0.289	0.397	CbGaD
Captopril—SLC22A6—Methotrexate—bone cancer	0.00907	0.258	CbGbCtD
Captopril—ALB—Methotrexate—bone cancer	0.00772	0.22	CbGbCtD
Captopril—F2—knee—bone cancer	0.00624	0.0809	CbGeAlD
Captopril—ABCB1—Cisplatin—bone cancer	0.00622	0.177	CbGbCtD
Captopril—MMP9—periosteum—bone cancer	0.00492	0.0638	CbGeAlD
Captopril—REN—arm—bone cancer	0.00419	0.0543	CbGeAlD
Captopril—ABCB1—Doxorubicin—bone cancer	0.00417	0.119	CbGbCtD
Captopril—ABCB1—Methotrexate—bone cancer	0.00404	0.115	CbGbCtD
Captopril—MMP2—hindlimb—bone cancer	0.00403	0.0523	CbGeAlD
Captopril—MMP2—cartilage tissue—bone cancer	0.00397	0.0514	CbGeAlD
Captopril—CYP2D6—Doxorubicin—bone cancer	0.00393	0.112	CbGbCtD
Captopril—REN—appendage—bone cancer	0.00376	0.0488	CbGeAlD
Captopril—F2—vertebral column—bone cancer	0.00356	0.0461	CbGeAlD
Captopril—MMP9—hindlimb—bone cancer	0.0035	0.0454	CbGeAlD
Captopril—MMP2—appendage—bone cancer	0.00346	0.0448	CbGeAlD
Captopril—MMP9—cartilage tissue—bone cancer	0.00345	0.0447	CbGeAlD
Captopril—F2—leg—bone cancer	0.00342	0.0444	CbGeAlD
Captopril—F2—forelimb—bone cancer	0.0034	0.0441	CbGeAlD
Captopril—F2—hindlimb—bone cancer	0.00306	0.0397	CbGeAlD
Captopril—MMP9—appendage—bone cancer	0.00301	0.039	CbGeAlD
Captopril—F2—appendage—bone cancer	0.00262	0.034	CbGeAlD
Captopril—ACE—forelimb—bone cancer	0.00208	0.0269	CbGeAlD
Captopril—ACE—hindlimb—bone cancer	0.00187	0.0242	CbGeAlD
Captopril—ACE—arm—bone cancer	0.00178	0.0231	CbGeAlD
Captopril—ACE—appendage—bone cancer	0.0016	0.0208	CbGeAlD
Captopril—LTA4H—connective tissue—bone cancer	0.00139	0.018	CbGeAlD
Captopril—REN—connective tissue—bone cancer	0.00107	0.0139	CbGeAlD
Captopril—MMP2—connective tissue—bone cancer	0.000987	0.0128	CbGeAlD
Captopril—LTA4H—tendon—bone cancer	0.000956	0.0124	CbGeAlD
Captopril—LTA4H—bone marrow—bone cancer	0.000926	0.012	CbGeAlD
Captopril—LTA4H—spinal cord—bone cancer	0.000922	0.012	CbGeAlD
Captopril—MMP9—connective tissue—bone cancer	0.000858	0.0111	CbGeAlD
Captopril—F2—connective tissue—bone cancer	0.000749	0.00971	CbGeAlD
Captopril—MMP2—tendon—bone cancer	0.000678	0.00879	CbGeAlD
Captopril—MMP2—spinal cord—bone cancer	0.000654	0.00848	CbGeAlD
Captopril—MMP9—tendon—bone cancer	0.00059	0.00765	CbGeAlD
Captopril—MMP9—bone marrow—bone cancer	0.000571	0.00741	CbGeAlD
Captopril—MMP9—spinal cord—bone cancer	0.000569	0.00738	CbGeAlD
Captopril—F2—bone marrow—bone cancer	0.000498	0.00646	CbGeAlD
Captopril—F2—spinal cord—bone cancer	0.000496	0.00644	CbGeAlD
Captopril—Enalapril—CYP3A4—bone cancer	0.000492	1	CrCbGaD
Captopril—ACE—connective tissue—bone cancer	0.000457	0.00593	CbGeAlD
Captopril—MMP9—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—PLAU—bone cancer	0.000417	0.00509	CbGpPWpGaD
Captopril—MMP2—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP9—bone cancer	0.000417	0.00509	CbGpPWpGaD
Captopril—MMP9—amb2 Integrin signaling—MMP2—bone cancer	0.000408	0.00499	CbGpPWpGaD
Captopril—MMP9—Activation of Matrix Metalloproteinases—MMP2—bone cancer	0.000408	0.00499	CbGpPWpGaD
Captopril—MMP2—Collagen degradation—MMP9—bone cancer	0.000408	0.00499	CbGpPWpGaD
Captopril—F2—Folate Metabolism—DHFR—bone cancer	0.000403	0.00493	CbGpPWpGaD
Captopril—MMP2—Metabolism of proteins—MOGS—bone cancer	0.000399	0.00487	CbGpPWpGaD
Captopril—MMP2—ATF-2 transcription factor network—RB1—bone cancer	0.000398	0.00486	CbGpPWpGaD
Captopril—MMP2—Plasma membrane estrogen receptor signaling—MMP9—bone cancer	0.000384	0.00469	CbGpPWpGaD
Captopril—REN—Metabolism of proteins—TUBB2A—bone cancer	0.00038	0.00464	CbGpPWpGaD
Captopril—LTA4H—Metabolism—NT5C3A—bone cancer	0.000378	0.00463	CbGpPWpGaD
Captopril—MMP9—Endochondral Ossification—IGF1R—bone cancer	0.000365	0.00446	CbGpPWpGaD
Captopril—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—bone cancer	0.000364	0.00444	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—MOGS—bone cancer	0.000358	0.00438	CbGpPWpGaD
Captopril—MMP2—Extracellular matrix organization—LOX—bone cancer	0.000358	0.00438	CbGpPWpGaD
Captopril—MMP9—Collagen degradation—MMP2—bone cancer	0.000356	0.00435	CbGpPWpGaD
Captopril—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000352	0.0043	CbGpPWpGaD
Captopril—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000348	0.00425	CbGpPWpGaD
Captopril—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000346	0.00423	CbGpPWpGaD
Captopril—MMP9—FGF signaling pathway—PLAU—bone cancer	0.000341	0.00417	CbGpPWpGaD
Captopril—MMP2—EPH-ephrin mediated repulsion of cells—MMP9—bone cancer	0.000338	0.00414	CbGpPWpGaD
Captopril—MMP9—Plasma membrane estrogen receptor signaling—MMP2—bone cancer	0.000335	0.00409	CbGpPWpGaD
Captopril—MMP9—Osteopontin-mediated events—JUN—bone cancer	0.000324	0.00396	CbGpPWpGaD
Captopril—MMP9—FGF signaling pathway—MET—bone cancer	0.000322	0.00394	CbGpPWpGaD
Captopril—ACE—bone marrow—bone cancer	0.000305	0.00395	CbGeAlD
Captopril—ACE—spinal cord—bone cancer	0.000303	0.00393	CbGeAlD
Captopril—Jaundice cholestatic—Doxorubicin—bone cancer	0.0003	0.00386	CcSEcCtD
Captopril—F2—IL1 and megakaryotyces in obesity—MMP9—bone cancer	0.000298	0.00365	CbGpPWpGaD
Captopril—MMP9—Endochondral Ossification—PLAU—bone cancer	0.000297	0.00364	CbGpPWpGaD
Captopril—MMP9—EPH-ephrin mediated repulsion of cells—MMP2—bone cancer	0.000295	0.00361	CbGpPWpGaD
Captopril—MMP2—ATF-2 transcription factor network—JUN—bone cancer	0.000295	0.0036	CbGpPWpGaD
Captopril—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000291	0.00356	CbGpPWpGaD
Captopril—Glossitis—Doxorubicin—bone cancer	0.000286	0.00368	CcSEcCtD
Captopril—Oliguria—Doxorubicin—bone cancer	0.000286	0.00368	CcSEcCtD
Captopril—Hepatocellular injury—Epirubicin—bone cancer	0.000285	0.00367	CcSEcCtD
Captopril—MMP9—Validated transcriptional targets of AP1 family members Fra1 and Fra2—JUN—bone cancer	0.000281	0.00343	CbGpPWpGaD
Captopril—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00028	0.00342	CbGpPWpGaD
Captopril—Hyperkalaemia—Epirubicin—bone cancer	0.00028	0.00361	CcSEcCtD
Captopril—Ulcer—Doxorubicin—bone cancer	0.000278	0.00359	CcSEcCtD
Captopril—MMP9—AP-1 transcription factor network—PLAU—bone cancer	0.000277	0.00339	CbGpPWpGaD
Captopril—MMP2—LPA receptor mediated events—JUN—bone cancer	0.000276	0.00338	CbGpPWpGaD
Captopril—Urine output increased—Methotrexate—bone cancer	0.000275	0.00355	CcSEcCtD
Captopril—Gynaecomastia—Methotrexate—bone cancer	0.000272	0.00351	CcSEcCtD
Captopril—MMP2—AGE/RAGE pathway—JUN—bone cancer	0.00027	0.00329	CbGpPWpGaD
Captopril—MMP2—LPA receptor mediated events—MMP9—bone cancer	0.000269	0.00329	CbGpPWpGaD
Captopril—MMP2—Extracellular matrix organization—SPARC—bone cancer	0.000268	0.00328	CbGpPWpGaD
Captopril—REN—Metabolism of proteins—EIF2S1—bone cancer	0.000265	0.00324	CbGpPWpGaD
Captopril—Hepatocellular injury—Doxorubicin—bone cancer	0.000263	0.0034	CcSEcCtD
Captopril—Dry eye—Epirubicin—bone cancer	0.000263	0.00339	CcSEcCtD
Captopril—MMP2—AGE/RAGE pathway—MMP9—bone cancer	0.000262	0.00321	CbGpPWpGaD
Captopril—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000259	0.00317	CbGpPWpGaD
Captopril—Lymphadenopathy—Methotrexate—bone cancer	0.000259	0.00334	CcSEcCtD
Captopril—Hyperkalaemia—Doxorubicin—bone cancer	0.000259	0.00334	CcSEcCtD
Captopril—Flushing—Cisplatin—bone cancer	0.000258	0.00333	CcSEcCtD
Captopril—F2—G alpha (q) signalling events—GRM1—bone cancer	0.000254	0.00311	CbGpPWpGaD
Captopril—Diabetes mellitus—Methotrexate—bone cancer	0.000254	0.00327	CcSEcCtD
Captopril—MMP9—TWEAK Signaling Pathway—JUN—bone cancer	0.000254	0.0031	CbGpPWpGaD
Captopril—Photosensitivity—Methotrexate—bone cancer	0.000251	0.00324	CcSEcCtD
Captopril—Polyuria—Methotrexate—bone cancer	0.000251	0.00324	CcSEcCtD
Captopril—Alopecia—Cisplatin—bone cancer	0.000246	0.00317	CcSEcCtD
Captopril—F2—Complement and Coagulation Cascades—PLAU—bone cancer	0.000245	0.003	CbGpPWpGaD
Captopril—Dry eye—Doxorubicin—bone cancer	0.000243	0.00314	CcSEcCtD
Captopril—Lymphadenopathy—Epirubicin—bone cancer	0.000242	0.00312	CcSEcCtD
Captopril—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000239	0.00293	CbGpPWpGaD
Captopril—Renal failure acute—Methotrexate—bone cancer	0.000239	0.00308	CcSEcCtD
Captopril—MMP9—Validated targets of C-MYC transcriptional activation—CDK4—bone cancer	0.000238	0.0029	CbGpPWpGaD
Captopril—Diabetes mellitus—Epirubicin—bone cancer	0.000238	0.00306	CcSEcCtD
Captopril—F2—Syndecan-4-mediated signaling events—MMP9—bone cancer	0.000237	0.0029	CbGpPWpGaD
Captopril—Photosensitivity—Epirubicin—bone cancer	0.000235	0.00303	CcSEcCtD
Captopril—MMP9—Extracellular matrix organization—LOX—bone cancer	0.000235	0.00287	CbGpPWpGaD
Captopril—MMP9—LPA receptor mediated events—MMP2—bone cancer	0.000235	0.00287	CbGpPWpGaD
Captopril—Dermatitis exfoliative—Methotrexate—bone cancer	0.000234	0.00302	CcSEcCtD
Captopril—MMP2—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	0.000231	0.00282	CbGpPWpGaD
Captopril—MMP2—Direct p53 effectors—MET—bone cancer	0.000229	0.0028	CbGpPWpGaD
Captopril—MMP9—AGE/RAGE pathway—MMP2—bone cancer	0.000229	0.0028	CbGpPWpGaD
Captopril—Vision blurred—Cisplatin—bone cancer	0.000228	0.00294	CcSEcCtD
Captopril—Anaphylactoid reaction—Methotrexate—bone cancer	0.000228	0.00294	CcSEcCtD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000227	0.00278	CbGpPWpGaD
Captopril—Cerebrovascular accident—Methotrexate—bone cancer	0.000225	0.0029	CcSEcCtD
Captopril—MMP2—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	0.000225	0.00275	CbGpPWpGaD
Captopril—Ill-defined disorder—Cisplatin—bone cancer	0.000225	0.0029	CcSEcCtD
Captopril—Lymphadenopathy—Doxorubicin—bone cancer	0.000224	0.00289	CcSEcCtD
Captopril—Anaemia—Cisplatin—bone cancer	0.000224	0.00289	CcSEcCtD
Captopril—Renal failure acute—Epirubicin—bone cancer	0.000224	0.00289	CcSEcCtD
Captopril—F2—Angiopoietin receptor Tie2-mediated signaling—MMP2—bone cancer	0.000221	0.0027	CbGpPWpGaD
Captopril—Diabetes mellitus—Doxorubicin—bone cancer	0.00022	0.00283	CcSEcCtD
Captopril—Dermatitis exfoliative—Epirubicin—bone cancer	0.000219	0.00282	CcSEcCtD
Captopril—Malaise—Cisplatin—bone cancer	0.000218	0.00282	CcSEcCtD
Captopril—MMP2—Metabolism of proteins—TUBB4B—bone cancer	0.000218	0.00267	CbGpPWpGaD
Captopril—Photosensitivity—Doxorubicin—bone cancer	0.000218	0.00281	CcSEcCtD
Captopril—MMP2—LPA receptor mediated events—EGFR—bone cancer	0.000217	0.00265	CbGpPWpGaD
Captopril—Dermatitis bullous—Epirubicin—bone cancer	0.000216	0.00279	CcSEcCtD
Captopril—Anaphylactoid reaction—Epirubicin—bone cancer	0.000213	0.00275	CcSEcCtD
Captopril—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000212	0.00259	CbGpPWpGaD
Captopril—MMP2—AGE/RAGE pathway—EGFR—bone cancer	0.000212	0.00259	CbGpPWpGaD
Captopril—Cerebrovascular accident—Epirubicin—bone cancer	0.000211	0.00272	CcSEcCtD
Captopril—Ataxia—Methotrexate—bone cancer	0.000208	0.00268	CcSEcCtD
Captopril—MMP9—FGF signaling pathway—JUN—bone cancer	0.000208	0.00254	CbGpPWpGaD
Captopril—Hyponatraemia—Epirubicin—bone cancer	0.000207	0.00267	CcSEcCtD
Captopril—Renal failure acute—Doxorubicin—bone cancer	0.000207	0.00267	CcSEcCtD
Captopril—MMP2—Degradation of the extracellular matrix—MMP9—bone cancer	0.000206	0.00252	CbGpPWpGaD
Captopril—Myalgia—Cisplatin—bone cancer	0.000206	0.00266	CcSEcCtD
Captopril—Discomfort—Cisplatin—bone cancer	0.000204	0.00263	CcSEcCtD
Captopril—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000203	0.00261	CcSEcCtD
Captopril—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000202	0.00247	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—MOGS—bone cancer	0.000202	0.00247	CbGpPWpGaD
Captopril—Dermatitis bullous—Doxorubicin—bone cancer	0.0002	0.00258	CcSEcCtD
Captopril—MMP9—Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling—EGFR—bone cancer	0.0002	0.00244	CbGpPWpGaD
Captopril—MMP2—Direct p53 effectors—RB1—bone cancer	0.000199	0.00244	CbGpPWpGaD
Captopril—Anaphylactic shock—Cisplatin—bone cancer	0.000198	0.00255	CcSEcCtD
Captopril—MMP2—EPH-Ephrin signaling—MMP9—bone cancer	0.000198	0.00242	CbGpPWpGaD
Captopril—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000197	0.00255	CcSEcCtD
Captopril—Cardiac arrest—Epirubicin—bone cancer	0.000196	0.00253	CcSEcCtD
Captopril—ACE—Metabolism of proteins—TUBB4B—bone cancer	0.000196	0.0024	CbGpPWpGaD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—bone cancer	0.000196	0.0024	CbGpPWpGaD
Captopril—Cerebrovascular accident—Doxorubicin—bone cancer	0.000195	0.00252	CcSEcCtD
Captopril—Ataxia—Epirubicin—bone cancer	0.000194	0.0025	CcSEcCtD
Captopril—Thrombocytopenia—Cisplatin—bone cancer	0.000194	0.0025	CcSEcCtD
Captopril—Tachycardia—Cisplatin—bone cancer	0.000193	0.00249	CcSEcCtD
Captopril—Hyponatraemia—Doxorubicin—bone cancer	0.000192	0.00247	CcSEcCtD
Captopril—Eosinophilia—Methotrexate—bone cancer	0.000189	0.00244	CcSEcCtD
Captopril—Orthostatic hypotension—Epirubicin—bone cancer	0.000189	0.00243	CcSEcCtD
Captopril—MMP2—Metabolism of proteins—TUBB2A—bone cancer	0.000189	0.00231	CbGpPWpGaD
Captopril—Anorexia—Cisplatin—bone cancer	0.000188	0.00243	CcSEcCtD
Captopril—Pancreatitis—Methotrexate—bone cancer	0.000187	0.00241	CcSEcCtD
Captopril—Hypotension—Cisplatin—bone cancer	0.000185	0.00238	CcSEcCtD
Captopril—Muscular weakness—Epirubicin—bone cancer	0.000182	0.00235	CcSEcCtD
Captopril—Cardiac arrest—Doxorubicin—bone cancer	0.000182	0.00234	CcSEcCtD
Captopril—Pancytopenia—Methotrexate—bone cancer	0.000181	0.00234	CcSEcCtD
Captopril—MMP9—LPA receptor mediated events—JUN—bone cancer	0.000181	0.00222	CbGpPWpGaD
Captopril—MMP9—Degradation of the extracellular matrix—MMP2—bone cancer	0.00018	0.0022	CbGpPWpGaD
Captopril—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00018	0.00232	CcSEcCtD
Captopril—Ataxia—Doxorubicin—bone cancer	0.00018	0.00232	CcSEcCtD
Captopril—Neutropenia—Methotrexate—bone cancer	0.000178	0.0023	CcSEcCtD
Captopril—Paraesthesia—Cisplatin—bone cancer	0.000178	0.00229	CcSEcCtD
Captopril—Eosinophilia—Epirubicin—bone cancer	0.000177	0.00228	CcSEcCtD
Captopril—MMP9—AGE/RAGE pathway—JUN—bone cancer	0.000177	0.00216	CbGpPWpGaD
Captopril—Dyspnoea—Cisplatin—bone cancer	0.000176	0.00227	CcSEcCtD
Captopril—MMP9—Extracellular matrix organization—SPARC—bone cancer	0.000176	0.00215	CbGpPWpGaD
Captopril—Erectile dysfunction—Methotrexate—bone cancer	0.000176	0.00227	CcSEcCtD
Captopril—Pancreatitis—Epirubicin—bone cancer	0.000175	0.00226	CcSEcCtD
Captopril—Orthostatic hypotension—Doxorubicin—bone cancer	0.000175	0.00225	CcSEcCtD
Captopril—Photosensitivity reaction—Methotrexate—bone cancer	0.000174	0.00225	CcSEcCtD
Captopril—Angina pectoris—Epirubicin—bone cancer	0.000174	0.00224	CcSEcCtD
Captopril—MMP9—EPH-Ephrin signaling—MMP2—bone cancer	0.000172	0.00211	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—CDK4—bone cancer	0.000172	0.00211	CbGpPWpGaD
Captopril—Decreased appetite—Cisplatin—bone cancer	0.000172	0.00222	CcSEcCtD
Captopril—MMP2—Direct p53 effectors—MDM2—bone cancer	0.00017	0.00208	CbGpPWpGaD
Captopril—Pancytopenia—Epirubicin—bone cancer	0.00017	0.00219	CcSEcCtD
Captopril—ACE—Metabolism of proteins—TUBB2A—bone cancer	0.00017	0.00207	CbGpPWpGaD
Captopril—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000169	0.00217	CcSEcCtD
Captopril—MMP9—AP-1 transcription factor network—JUN—bone cancer	0.000169	0.00206	CbGpPWpGaD
Captopril—Muscular weakness—Doxorubicin—bone cancer	0.000169	0.00217	CcSEcCtD
Captopril—Renal failure—Methotrexate—bone cancer	0.000167	0.00216	CcSEcCtD
Captopril—Neutropenia—Epirubicin—bone cancer	0.000167	0.00215	CcSEcCtD
Captopril—Stomatitis—Methotrexate—bone cancer	0.000166	0.00214	CcSEcCtD
Captopril—LTA4H—Metabolism—ENO2—bone cancer	0.000166	0.00203	CbGpPWpGaD
Captopril—Pollakiuria—Epirubicin—bone cancer	0.000165	0.00213	CcSEcCtD
Captopril—F2—G alpha (q) signalling events—GNA11—bone cancer	0.000164	0.002	CbGpPWpGaD
Captopril—Eosinophilia—Doxorubicin—bone cancer	0.000164	0.00211	CcSEcCtD
Captopril—Photosensitivity reaction—Epirubicin—bone cancer	0.000163	0.0021	CcSEcCtD
Captopril—Feeling abnormal—Cisplatin—bone cancer	0.000163	0.0021	CcSEcCtD
Captopril—Pancreatitis—Doxorubicin—bone cancer	0.000162	0.00209	CcSEcCtD
Captopril—Weight decreased—Epirubicin—bone cancer	0.000162	0.00208	CcSEcCtD
Captopril—Angina pectoris—Doxorubicin—bone cancer	0.000161	0.00208	CcSEcCtD
Captopril—ALB—Folate Metabolism—DHFR—bone cancer	0.00016	0.00196	CbGpPWpGaD
Captopril—Agranulocytosis—Methotrexate—bone cancer	0.000159	0.00205	CcSEcCtD
Captopril—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000158	0.00204	CcSEcCtD
Captopril—Pancytopenia—Doxorubicin—bone cancer	0.000157	0.00202	CcSEcCtD
Captopril—F2—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000157	0.00192	CbGpPWpGaD
Captopril—Renal failure—Epirubicin—bone cancer	0.000156	0.00202	CcSEcCtD
Captopril—Body temperature increased—Cisplatin—bone cancer	0.000156	0.00202	CcSEcCtD
Captopril—Stomatitis—Epirubicin—bone cancer	0.000155	0.002	CcSEcCtD
Captopril—Jaundice—Epirubicin—bone cancer	0.000155	0.002	CcSEcCtD
Captopril—Neutropenia—Doxorubicin—bone cancer	0.000154	0.00199	CcSEcCtD
Captopril—LTA4H—Metabolism—DHFR—bone cancer	0.000154	0.00188	CbGpPWpGaD
Captopril—Hepatitis—Methotrexate—bone cancer	0.000153	0.00197	CcSEcCtD
Captopril—Pollakiuria—Doxorubicin—bone cancer	0.000153	0.00197	CcSEcCtD
Captopril—Pharyngitis—Methotrexate—bone cancer	0.000152	0.00195	CcSEcCtD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	0.000152	0.00185	CbGpPWpGaD
Captopril—Photosensitivity reaction—Doxorubicin—bone cancer	0.000151	0.00194	CcSEcCtD
Captopril—MMP9—Spinal Cord Injury—RB1—bone cancer	0.00015	0.00183	CbGpPWpGaD
Captopril—Weight decreased—Doxorubicin—bone cancer	0.000149	0.00193	CcSEcCtD
Captopril—Agranulocytosis—Epirubicin—bone cancer	0.000149	0.00192	CcSEcCtD
Captopril—F2—GPCR ligand binding—GRM4—bone cancer	0.000148	0.00181	CbGpPWpGaD
Captopril—MMP2—Direct p53 effectors—JUN—bone cancer	0.000148	0.00181	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000147	0.00179	CbGpPWpGaD
Captopril—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000146	0.00188	CcSEcCtD
Captopril—Renal failure—Doxorubicin—bone cancer	0.000145	0.00187	CcSEcCtD
Captopril—Erythema multiforme—Methotrexate—bone cancer	0.000144	0.00186	CcSEcCtD
Captopril—LTA4H—Metabolism—GNA11—bone cancer	0.000144	0.00176	CbGpPWpGaD
Captopril—Stomatitis—Doxorubicin—bone cancer	0.000144	0.00185	CcSEcCtD
Captopril—Jaundice—Doxorubicin—bone cancer	0.000144	0.00185	CcSEcCtD
Captopril—F2—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000143	0.00175	CbGpPWpGaD
Captopril—Rhinitis—Epirubicin—bone cancer	0.000143	0.00185	CcSEcCtD
Captopril—Hepatitis—Epirubicin—bone cancer	0.000143	0.00184	CcSEcCtD
Captopril—MMP9—LPA receptor mediated events—EGFR—bone cancer	0.000142	0.00174	CbGpPWpGaD
Captopril—Asthenia—Cisplatin—bone cancer	0.000142	0.00183	CcSEcCtD
Captopril—Pharyngitis—Epirubicin—bone cancer	0.000142	0.00183	CcSEcCtD
Captopril—MMP9—Signaling by SCF-KIT—KIT—bone cancer	0.000141	0.00172	CbGpPWpGaD
Captopril—ALB—Platelet degranulation—SPARC—bone cancer	0.00014	0.00171	CbGpPWpGaD
Captopril—MMP9—AGE/RAGE pathway—EGFR—bone cancer	0.000139	0.0017	CbGpPWpGaD
Captopril—Agranulocytosis—Doxorubicin—bone cancer	0.000137	0.00177	CcSEcCtD
Captopril—Diarrhoea—Cisplatin—bone cancer	0.000135	0.00174	CcSEcCtD
Captopril—Erythema multiforme—Epirubicin—bone cancer	0.000135	0.00174	CcSEcCtD
Captopril—Alopecia—Methotrexate—bone cancer	0.000135	0.00174	CcSEcCtD
Captopril—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000134	0.00163	CbGpPWpGaD
Captopril—Flushing—Epirubicin—bone cancer	0.000133	0.00171	CcSEcCtD
Captopril—Rhinitis—Doxorubicin—bone cancer	0.000133	0.00171	CcSEcCtD
Captopril—Hepatitis—Doxorubicin—bone cancer	0.000132	0.00171	CcSEcCtD
Captopril—MMP2—Metabolism of proteins—EIF2S1—bone cancer	0.000132	0.00161	CbGpPWpGaD
Captopril—Pharyngitis—Doxorubicin—bone cancer	0.000131	0.00169	CcSEcCtD
Captopril—LTA4H—Metabolism—CYP3A4—bone cancer	0.00013	0.00159	CbGpPWpGaD
Captopril—Dysgeusia—Methotrexate—bone cancer	0.00013	0.00168	CcSEcCtD
Captopril—F2—Platelet activation, signaling and aggregation—IL3—bone cancer	0.00013	0.00159	CbGpPWpGaD
Captopril—LTA4H—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.00013	0.00158	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—GRM1—bone cancer	0.000128	0.00157	CbGpPWpGaD
Captopril—Alopecia—Epirubicin—bone cancer	0.000126	0.00163	CcSEcCtD
Captopril—Vomiting—Cisplatin—bone cancer	0.000126	0.00162	CcSEcCtD
Captopril—Vision blurred—Methotrexate—bone cancer	0.000125	0.00162	CcSEcCtD
Captopril—SLC15A1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000125	0.00153	CbGpPWpGaD
Captopril—Erythema multiforme—Doxorubicin—bone cancer	0.000125	0.00161	CcSEcCtD
Captopril—Rash—Cisplatin—bone cancer	0.000125	0.00161	CcSEcCtD
Captopril—Dermatitis—Cisplatin—bone cancer	0.000125	0.00161	CcSEcCtD
Captopril—Ill-defined disorder—Methotrexate—bone cancer	0.000123	0.00159	CcSEcCtD
Captopril—MMP9—Spinal Cord Injury—PTGS2—bone cancer	0.000123	0.00151	CbGpPWpGaD
Captopril—Anaemia—Methotrexate—bone cancer	0.000123	0.00158	CcSEcCtD
Captopril—Flushing—Doxorubicin—bone cancer	0.000123	0.00158	CcSEcCtD
Captopril—Tension—Epirubicin—bone cancer	0.000122	0.00157	CcSEcCtD
Captopril—Dysgeusia—Epirubicin—bone cancer	0.000122	0.00157	CcSEcCtD
Captopril—Nervousness—Epirubicin—bone cancer	0.000121	0.00156	CcSEcCtD
Captopril—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000121	0.00148	CbGpPWpGaD
Captopril—F2—Selenium Micronutrient Network—PTGS2—bone cancer	0.00012	0.00147	CbGpPWpGaD
Captopril—Malaise—Methotrexate—bone cancer	0.00012	0.00155	CcSEcCtD
Captopril—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000119	0.00146	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—EIF2S1—bone cancer	0.000118	0.00145	CbGpPWpGaD
Captopril—Nausea—Cisplatin—bone cancer	0.000117	0.00151	CcSEcCtD
Captopril—Vision blurred—Epirubicin—bone cancer	0.000117	0.00151	CcSEcCtD
Captopril—MMP2—Axon guidance—MET—bone cancer	0.000117	0.00143	CbGpPWpGaD
Captopril—Alopecia—Doxorubicin—bone cancer	0.000117	0.00151	CcSEcCtD
Captopril—MMP2—Direct p53 effectors—EGFR—bone cancer	0.000116	0.00142	CbGpPWpGaD
Captopril—Cough—Methotrexate—bone cancer	0.000116	0.0015	CcSEcCtD
Captopril—Ill-defined disorder—Epirubicin—bone cancer	0.000115	0.00149	CcSEcCtD
Captopril—Anaemia—Epirubicin—bone cancer	0.000115	0.00148	CcSEcCtD
Captopril—Chest pain—Methotrexate—bone cancer	0.000113	0.00146	CcSEcCtD
Captopril—Arthralgia—Methotrexate—bone cancer	0.000113	0.00146	CcSEcCtD
Captopril—Myalgia—Methotrexate—bone cancer	0.000113	0.00146	CcSEcCtD
Captopril—Tension—Doxorubicin—bone cancer	0.000113	0.00146	CcSEcCtD
Captopril—Dysgeusia—Doxorubicin—bone cancer	0.000113	0.00145	CcSEcCtD
Captopril—Malaise—Epirubicin—bone cancer	0.000112	0.00145	CcSEcCtD
Captopril—Discomfort—Methotrexate—bone cancer	0.000112	0.00144	CcSEcCtD
Captopril—Nervousness—Doxorubicin—bone cancer	0.000112	0.00144	CcSEcCtD
Captopril—Syncope—Epirubicin—bone cancer	0.000112	0.00144	CcSEcCtD
Captopril—LTA4H—Metabolism—GSTP1—bone cancer	0.000111	0.00136	CbGpPWpGaD
Captopril—MMP9—AP-1 transcription factor network—TP53—bone cancer	0.000111	0.00136	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—MDM2—bone cancer	0.000111	0.00135	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—TUBB4B—bone cancer	0.000111	0.00135	CbGpPWpGaD
Captopril—Palpitations—Epirubicin—bone cancer	0.00011	0.00142	CcSEcCtD
Captopril—Confusional state—Methotrexate—bone cancer	0.000109	0.00141	CcSEcCtD
Captopril—Loss of consciousness—Epirubicin—bone cancer	0.000109	0.00141	CcSEcCtD
Captopril—Cough—Epirubicin—bone cancer	0.000109	0.0014	CcSEcCtD
Captopril—Anaphylactic shock—Methotrexate—bone cancer	0.000108	0.0014	CcSEcCtD
Captopril—Vision blurred—Doxorubicin—bone cancer	0.000108	0.0014	CcSEcCtD
Captopril—REN—Metabolism of proteins—MMP2—bone cancer	0.000108	0.00132	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000108	0.00132	CbGpPWpGaD
Captopril—ABCB1—bone marrow—bone cancer	0.000107	0.00139	CbGeAlD
Captopril—Ill-defined disorder—Doxorubicin—bone cancer	0.000107	0.00138	CcSEcCtD
Captopril—ABCB1—spinal cord—bone cancer	0.000107	0.00138	CbGeAlD
Captopril—Anaemia—Doxorubicin—bone cancer	0.000106	0.00137	CcSEcCtD
Captopril—Thrombocytopenia—Methotrexate—bone cancer	0.000106	0.00137	CcSEcCtD
Captopril—Arthralgia—Epirubicin—bone cancer	0.000106	0.00137	CcSEcCtD
Captopril—Chest pain—Epirubicin—bone cancer	0.000106	0.00137	CcSEcCtD
Captopril—Myalgia—Epirubicin—bone cancer	0.000106	0.00137	CcSEcCtD
Captopril—Discomfort—Epirubicin—bone cancer	0.000105	0.00135	CcSEcCtD
Captopril—Malaise—Doxorubicin—bone cancer	0.000104	0.00134	CcSEcCtD
Captopril—Dry mouth—Epirubicin—bone cancer	0.000104	0.00134	CcSEcCtD
Captopril—Anorexia—Methotrexate—bone cancer	0.000103	0.00133	CcSEcCtD
Captopril—Syncope—Doxorubicin—bone cancer	0.000103	0.00133	CcSEcCtD
Captopril—Confusional state—Epirubicin—bone cancer	0.000102	0.00132	CcSEcCtD
Captopril—Palpitations—Doxorubicin—bone cancer	0.000102	0.00131	CcSEcCtD
Captopril—Anaphylactic shock—Epirubicin—bone cancer	0.000102	0.00131	CcSEcCtD
Captopril—Hypotension—Methotrexate—bone cancer	0.000101	0.00131	CcSEcCtD
Captopril—Loss of consciousness—Doxorubicin—bone cancer	0.000101	0.0013	CcSEcCtD
Captopril—MMP9—Validated targets of C-MYC transcriptional activation—TP53—bone cancer	0.000101	0.00124	CbGpPWpGaD
Captopril—Cough—Doxorubicin—bone cancer	0.0001	0.0013	CcSEcCtD
Captopril—Shock—Epirubicin—bone cancer	9.99e-05	0.00129	CcSEcCtD
Captopril—Thrombocytopenia—Epirubicin—bone cancer	9.94e-05	0.00128	CcSEcCtD
Captopril—Tachycardia—Epirubicin—bone cancer	9.91e-05	0.00128	CcSEcCtD
Captopril—Musculoskeletal discomfort—Methotrexate—bone cancer	9.89e-05	0.00127	CcSEcCtD
Captopril—Insomnia—Methotrexate—bone cancer	9.81e-05	0.00127	CcSEcCtD
Captopril—Arthralgia—Doxorubicin—bone cancer	9.8e-05	0.00126	CcSEcCtD
Captopril—Chest pain—Doxorubicin—bone cancer	9.8e-05	0.00126	CcSEcCtD
Captopril—Myalgia—Doxorubicin—bone cancer	9.8e-05	0.00126	CcSEcCtD
Captopril—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	9.79e-05	0.0012	CbGpPWpGaD
Captopril—F2—Regulation of Actin Cytoskeleton—BRAF—bone cancer	9.77e-05	0.00119	CbGpPWpGaD
Captopril—MMP2—Direct p53 effectors—TP53—bone cancer	9.75e-05	0.00119	CbGpPWpGaD
Captopril—Paraesthesia—Methotrexate—bone cancer	9.74e-05	0.00126	CcSEcCtD
Captopril—Discomfort—Doxorubicin—bone cancer	9.68e-05	0.00125	CcSEcCtD
Captopril—Anorexia—Epirubicin—bone cancer	9.68e-05	0.00125	CcSEcCtD
Captopril—Dyspnoea—Methotrexate—bone cancer	9.67e-05	0.00125	CcSEcCtD
Captopril—Somnolence—Methotrexate—bone cancer	9.65e-05	0.00124	CcSEcCtD
Captopril—Dry mouth—Doxorubicin—bone cancer	9.58e-05	0.00124	CcSEcCtD
Captopril—Dyspepsia—Methotrexate—bone cancer	9.55e-05	0.00123	CcSEcCtD
Captopril—F2—Metabolism of proteins—TUBB2A—bone cancer	9.55e-05	0.00117	CbGpPWpGaD
Captopril—Hypotension—Epirubicin—bone cancer	9.49e-05	0.00122	CcSEcCtD
Captopril—Confusional state—Doxorubicin—bone cancer	9.47e-05	0.00122	CcSEcCtD
Captopril—Decreased appetite—Methotrexate—bone cancer	9.43e-05	0.00122	CcSEcCtD
Captopril—Anaphylactic shock—Doxorubicin—bone cancer	9.39e-05	0.00121	CcSEcCtD
Captopril—Fatigue—Methotrexate—bone cancer	9.35e-05	0.00121	CcSEcCtD
Captopril—SLC22A6—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.29e-05	0.00114	CbGpPWpGaD
Captopril—Musculoskeletal discomfort—Epirubicin—bone cancer	9.25e-05	0.00119	CcSEcCtD
Captopril—Shock—Doxorubicin—bone cancer	9.24e-05	0.00119	CcSEcCtD
Captopril—Thrombocytopenia—Doxorubicin—bone cancer	9.2e-05	0.00119	CcSEcCtD
Captopril—Insomnia—Epirubicin—bone cancer	9.18e-05	0.00118	CcSEcCtD
Captopril—Tachycardia—Doxorubicin—bone cancer	9.17e-05	0.00118	CcSEcCtD
Captopril—Paraesthesia—Epirubicin—bone cancer	9.12e-05	0.00118	CcSEcCtD
Captopril—Dyspnoea—Epirubicin—bone cancer	9.05e-05	0.00117	CcSEcCtD
Captopril—F2—GPCR ligand binding—SMO—bone cancer	9.03e-05	0.0011	CbGpPWpGaD
Captopril—Somnolence—Epirubicin—bone cancer	9.03e-05	0.00116	CcSEcCtD
Captopril—F2—Folate Metabolism—TP53—bone cancer	9.01e-05	0.0011	CbGpPWpGaD
Captopril—Anorexia—Doxorubicin—bone cancer	8.96e-05	0.00115	CcSEcCtD
Captopril—Feeling abnormal—Methotrexate—bone cancer	8.94e-05	0.00115	CcSEcCtD
Captopril—Dyspepsia—Epirubicin—bone cancer	8.94e-05	0.00115	CcSEcCtD
Captopril—Gastrointestinal pain—Methotrexate—bone cancer	8.87e-05	0.00114	CcSEcCtD
Captopril—Decreased appetite—Epirubicin—bone cancer	8.83e-05	0.00114	CcSEcCtD
Captopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	8.8e-05	0.00108	CbGpPWpGaD
Captopril—Hypotension—Doxorubicin—bone cancer	8.78e-05	0.00113	CcSEcCtD
Captopril—Fatigue—Epirubicin—bone cancer	8.75e-05	0.00113	CcSEcCtD
Captopril—MMP9—Spinal Cord Injury—EGFR—bone cancer	8.73e-05	0.00107	CbGpPWpGaD
Captopril—Constipation—Epirubicin—bone cancer	8.68e-05	0.00112	CcSEcCtD
Captopril—MMP2—Extracellular matrix organization—MMP9—bone cancer	8.65e-05	0.00106	CbGpPWpGaD
Captopril—Abdominal pain—Methotrexate—bone cancer	8.58e-05	0.00111	CcSEcCtD
Captopril—Body temperature increased—Methotrexate—bone cancer	8.58e-05	0.00111	CcSEcCtD
Captopril—Musculoskeletal discomfort—Doxorubicin—bone cancer	8.56e-05	0.0011	CcSEcCtD
Captopril—Insomnia—Doxorubicin—bone cancer	8.5e-05	0.0011	CcSEcCtD
Captopril—Paraesthesia—Doxorubicin—bone cancer	8.44e-05	0.00109	CcSEcCtD
Captopril—Dyspnoea—Doxorubicin—bone cancer	8.38e-05	0.00108	CcSEcCtD
Captopril—Feeling abnormal—Epirubicin—bone cancer	8.37e-05	0.00108	CcSEcCtD
Captopril—MMP2—Developmental Biology—MET—bone cancer	8.36e-05	0.00102	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—CDK4—bone cancer	8.36e-05	0.00102	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—GRM4—bone cancer	8.36e-05	0.00102	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—RGS1—bone cancer	8.36e-05	0.00102	CbGpPWpGaD
Captopril—Somnolence—Doxorubicin—bone cancer	8.35e-05	0.00108	CcSEcCtD
Captopril—Gastrointestinal pain—Epirubicin—bone cancer	8.3e-05	0.00107	CcSEcCtD
Captopril—Dyspepsia—Doxorubicin—bone cancer	8.27e-05	0.00107	CcSEcCtD
Captopril—Decreased appetite—Doxorubicin—bone cancer	8.17e-05	0.00105	CcSEcCtD
Captopril—Fatigue—Doxorubicin—bone cancer	8.1e-05	0.00104	CcSEcCtD
Captopril—F2—Hemostasis—SPARC—bone cancer	8.08e-05	0.000987	CbGpPWpGaD
Captopril—Constipation—Doxorubicin—bone cancer	8.03e-05	0.00104	CcSEcCtD
Captopril—Abdominal pain—Epirubicin—bone cancer	8.03e-05	0.00104	CcSEcCtD
Captopril—Body temperature increased—Epirubicin—bone cancer	8.03e-05	0.00104	CcSEcCtD
Captopril—SLC22A6—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.02e-05	0.000981	CbGpPWpGaD
Captopril—Asthenia—Methotrexate—bone cancer	7.78e-05	0.001	CcSEcCtD
Captopril—Feeling abnormal—Doxorubicin—bone cancer	7.74e-05	0.000998	CcSEcCtD
Captopril—Gastrointestinal pain—Doxorubicin—bone cancer	7.68e-05	0.000991	CcSEcCtD
Captopril—MMP9—Axon guidance—MET—bone cancer	7.68e-05	0.000939	CbGpPWpGaD
Captopril—Pruritus—Methotrexate—bone cancer	7.68e-05	0.00099	CcSEcCtD
Captopril—F2—Signaling by GPCR—GRM4—bone cancer	7.59e-05	0.000928	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—RGS1—bone cancer	7.59e-05	0.000928	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—EGFR—bone cancer	7.57e-05	0.000926	CbGpPWpGaD
Captopril—MMP9—Extracellular matrix organization—MMP2—bone cancer	7.55e-05	0.000923	CbGpPWpGaD
Captopril—Abdominal pain—Doxorubicin—bone cancer	7.43e-05	0.000958	CcSEcCtD
Captopril—Body temperature increased—Doxorubicin—bone cancer	7.43e-05	0.000958	CcSEcCtD
Captopril—Diarrhoea—Methotrexate—bone cancer	7.42e-05	0.000957	CcSEcCtD
Captopril—F2—Hemostasis—GNA11—bone cancer	7.39e-05	0.000903	CbGpPWpGaD
Captopril—MMP2—Axon guidance—MMP9—bone cancer	7.34e-05	0.000898	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—TP53—bone cancer	7.33e-05	0.000896	CbGpPWpGaD
Captopril—Asthenia—Epirubicin—bone cancer	7.29e-05	0.000939	CcSEcCtD
Captopril—F2—GPCR downstream signaling—GRM1—bone cancer	7.24e-05	0.000886	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	7.2e-05	0.00088	CbGpPWpGaD
Captopril—Pruritus—Epirubicin—bone cancer	7.18e-05	0.000926	CcSEcCtD
Captopril—Dizziness—Methotrexate—bone cancer	7.17e-05	0.000925	CcSEcCtD
Captopril—Diarrhoea—Epirubicin—bone cancer	6.95e-05	0.000896	CcSEcCtD
Captopril—Vomiting—Methotrexate—bone cancer	6.9e-05	0.00089	CcSEcCtD
Captopril—Rash—Methotrexate—bone cancer	6.84e-05	0.000882	CcSEcCtD
Captopril—Dermatitis—Methotrexate—bone cancer	6.83e-05	0.000881	CcSEcCtD
Captopril—Headache—Methotrexate—bone cancer	6.8e-05	0.000876	CcSEcCtD
Captopril—Asthenia—Doxorubicin—bone cancer	6.74e-05	0.000869	CcSEcCtD
Captopril—Dizziness—Epirubicin—bone cancer	6.71e-05	0.000866	CcSEcCtD
Captopril—F2—Hemostasis—IL3—bone cancer	6.7e-05	0.000819	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—EIF2S1—bone cancer	6.66e-05	0.000814	CbGpPWpGaD
Captopril—Pruritus—Doxorubicin—bone cancer	6.65e-05	0.000857	CcSEcCtD
Captopril—F2—Signaling by GPCR—GRM1—bone cancer	6.58e-05	0.000804	CbGpPWpGaD
Captopril—Vomiting—Epirubicin—bone cancer	6.46e-05	0.000832	CcSEcCtD
Captopril—Nausea—Methotrexate—bone cancer	6.44e-05	0.000831	CcSEcCtD
Captopril—Diarrhoea—Doxorubicin—bone cancer	6.43e-05	0.000829	CcSEcCtD
Captopril—MMP9—Axon guidance—MMP2—bone cancer	6.41e-05	0.000783	CbGpPWpGaD
Captopril—Rash—Epirubicin—bone cancer	6.4e-05	0.000826	CcSEcCtD
Captopril—Dermatitis—Epirubicin—bone cancer	6.4e-05	0.000825	CcSEcCtD
Captopril—Headache—Epirubicin—bone cancer	6.36e-05	0.00082	CcSEcCtD
Captopril—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	6.22e-05	0.00076	CbGpPWpGaD
Captopril—Dizziness—Doxorubicin—bone cancer	6.21e-05	0.000801	CcSEcCtD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	6.12e-05	0.000748	CbGpPWpGaD
Captopril—Nausea—Epirubicin—bone cancer	6.03e-05	0.000778	CcSEcCtD
Captopril—Vomiting—Doxorubicin—bone cancer	5.97e-05	0.00077	CcSEcCtD
Captopril—MMP2—Axon guidance—EGFR—bone cancer	5.93e-05	0.000725	CbGpPWpGaD
Captopril—Rash—Doxorubicin—bone cancer	5.92e-05	0.000764	CcSEcCtD
Captopril—Dermatitis—Doxorubicin—bone cancer	5.92e-05	0.000763	CcSEcCtD
Captopril—Headache—Doxorubicin—bone cancer	5.89e-05	0.000759	CcSEcCtD
Captopril—MMP9—Signaling Pathways—GRM4—bone cancer	5.81e-05	0.00071	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—RGS1—bone cancer	5.81e-05	0.00071	CbGpPWpGaD
Captopril—LTA4H—Metabolism—PTGS2—bone cancer	5.77e-05	0.000706	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	5.69e-05	0.000695	CbGpPWpGaD
Captopril—F2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	5.59e-05	0.000684	CbGpPWpGaD
Captopril—Nausea—Doxorubicin—bone cancer	5.58e-05	0.00072	CcSEcCtD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	5.57e-05	0.000682	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—MET—bone cancer	5.48e-05	0.00067	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—CDK4—bone cancer	5.48e-05	0.00067	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—MMP9—bone cancer	5.24e-05	0.000641	CbGpPWpGaD
Captopril—CYP2D6—Biological oxidations—CYP3A4—bone cancer	5.2e-05	0.000636	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	5.16e-05	0.00063	CbGpPWpGaD
Captopril—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	5.13e-05	0.000627	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	5.08e-05	0.000621	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—GRM1—bone cancer	5.03e-05	0.000615	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	5.01e-05	0.000612	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—MMP2—bone cancer	4.84e-05	0.000591	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.83e-05	0.000591	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	4.77e-05	0.000583	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	4.75e-05	0.00058	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—GNA11—bone cancer	4.67e-05	0.000571	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—SMO—bone cancer	4.64e-05	0.000567	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—MMP2—bone cancer	4.57e-05	0.000559	CbGpPWpGaD
Captopril—F2—Signaling Pathways—RGS1—bone cancer	4.48e-05	0.000548	CbGpPWpGaD
Captopril—F2—Signaling Pathways—GRM4—bone cancer	4.48e-05	0.000548	CbGpPWpGaD
Captopril—CYP2D6—Biological oxidations—GSTP1—bone cancer	4.45e-05	0.000544	CbGpPWpGaD
Captopril—F2—Hemostasis—PLAU—bone cancer	4.39e-05	0.000537	CbGpPWpGaD
Captopril—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	4.39e-05	0.000536	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	4.24e-05	0.000519	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—GNA11—bone cancer	4.24e-05	0.000518	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—EGFR—bone cancer	4.23e-05	0.000518	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—IL3—bone cancer	4.23e-05	0.000517	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	4.23e-05	0.000517	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	4.17e-05	0.00051	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.17e-05	0.00051	CbGpPWpGaD
Captopril—MMP9—Axon guidance—EGFR—bone cancer	3.89e-05	0.000476	CbGpPWpGaD
Captopril—F2—Signaling Pathways—GRM1—bone cancer	3.89e-05	0.000475	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—IL3—bone cancer	3.84e-05	0.00047	CbGpPWpGaD
Captopril—ALB—Metabolism—NDUFA12—bone cancer	3.78e-05	0.000462	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	3.65e-05	0.000447	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—TP53—bone cancer	3.58e-05	0.000437	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—SMO—bone cancer	3.55e-05	0.000434	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NDUFA12—bone cancer	3.31e-05	0.000405	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—GNA11—bone cancer	3.24e-05	0.000397	CbGpPWpGaD
Captopril—ALB—Hemostasis—SPARC—bone cancer	3.2e-05	0.000392	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.15e-05	0.000385	CbGpPWpGaD
Captopril—ALB—Metabolism—NT5C3A—bone cancer	3.13e-05	0.000383	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NDUFA12—bone cancer	3.12e-05	0.000381	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—ATF1—bone cancer	3.02e-05	0.000369	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IL3—bone cancer	2.94e-05	0.00036	CbGpPWpGaD
Captopril—ALB—Hemostasis—GNA11—bone cancer	2.93e-05	0.000358	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—EGFR—bone cancer	2.78e-05	0.00034	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NT5C3A—bone cancer	2.74e-05	0.000335	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SMO—bone cancer	2.74e-05	0.000335	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—MMP2—bone cancer	2.72e-05	0.000333	CbGpPWpGaD
Captopril—ALB—Hemostasis—IL3—bone cancer	2.66e-05	0.000325	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NT5C3A—bone cancer	2.58e-05	0.000316	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TGFBR2—bone cancer	2.52e-05	0.000307	CbGpPWpGaD
Captopril—F2—Signaling Pathways—GNA11—bone cancer	2.5e-05	0.000306	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IGF1R—bone cancer	2.37e-05	0.000289	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.33e-05	0.000285	CbGpPWpGaD
Captopril—F2—Signaling Pathways—ATF1—bone cancer	2.33e-05	0.000285	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IL3—bone cancer	2.27e-05	0.000278	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.25e-05	0.000275	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.03e-05	0.000248	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TGFBR2—bone cancer	1.94e-05	0.000237	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IGF1R—bone cancer	1.83e-05	0.000223	CbGpPWpGaD
Captopril—F2—Hemostasis—TP53—bone cancer	1.77e-05	0.000216	CbGpPWpGaD
Captopril—ALB—Hemostasis—PLAU—bone cancer	1.74e-05	0.000213	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—KIT—bone cancer	1.72e-05	0.00021	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—BRAF—bone cancer	1.61e-05	0.000197	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.59e-05	0.000195	CbGpPWpGaD
Captopril—ALB—Metabolism—ENO2—bone cancer	1.37e-05	0.000168	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—MDM2—bone cancer	1.35e-05	0.000165	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.34e-05	0.000164	CbGpPWpGaD
Captopril—F2—Signaling Pathways—KIT—bone cancer	1.33e-05	0.000162	CbGpPWpGaD
Captopril—ALB—Metabolism—DHFR—bone cancer	1.27e-05	0.000155	CbGpPWpGaD
Captopril—F2—Signaling Pathways—BRAF—bone cancer	1.25e-05	0.000152	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—EGFR—bone cancer	1.21e-05	0.000148	CbGpPWpGaD
Captopril—ABCB1—Metabolism—ENO2—bone cancer	1.2e-05	0.000147	CbGpPWpGaD
Captopril—ALB—Metabolism—GNA11—bone cancer	1.19e-05	0.000145	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—JUN—bone cancer	1.17e-05	0.000144	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—ENO2—bone cancer	1.13e-05	0.000138	CbGpPWpGaD
Captopril—ABCB1—Metabolism—DHFR—bone cancer	1.11e-05	0.000136	CbGpPWpGaD
Captopril—ALB—Metabolism—CYP3A4—bone cancer	1.08e-05	0.000132	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.07e-05	0.000131	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—DHFR—bone cancer	1.05e-05	0.000128	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MDM2—bone cancer	1.04e-05	0.000128	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GNA11—bone cancer	1.04e-05	0.000127	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GNA11—bone cancer	9.81e-06	0.00012	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CYP3A4—bone cancer	9.44e-06	0.000115	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—EGFR—bone cancer	9.24e-06	0.000113	CbGpPWpGaD
Captopril—ALB—Metabolism—GSTP1—bone cancer	9.21e-06	0.000113	CbGpPWpGaD
Captopril—F2—Signaling Pathways—JUN—bone cancer	9.07e-06	0.000111	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CYP3A4—bone cancer	8.9e-06	0.000109	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MMP9—bone cancer	8.83e-06	0.000108	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSTP1—bone cancer	8.07e-06	9.87e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TP53—bone cancer	7.76e-06	9.48e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSTP1—bone cancer	7.61e-06	9.3e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—EGFR—bone cancer	7.13e-06	8.72e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—TP53—bone cancer	7.01e-06	8.57e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TP53—bone cancer	5.99e-06	7.32e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PTGS2—bone cancer	4.77e-06	5.84e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PTGS2—bone cancer	4.18e-06	5.11e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PTGS2—bone cancer	3.94e-06	4.82e-05	CbGpPWpGaD
